iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine
Key facts
- Who runs it
- Radboud University Medical Center
- Where
- Netherlands1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 10 people enrolled
- Started
- 1 May 2025
- Ended
- 31 Jul 2026
- Type of study
- Interventional
- Treatments tested
- Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B)
- Record updated
- 18 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- The patient is at least 18 years old on the day of inclusion
- The patient has suspected chronic pulmonary aspergillosis or ABPA
- There is no significant interference with standard care and follow-up
Who cannot take part
- The patient has been receiving antifungal treatment for more than 48 hours prior to the study day
- The patient has severe kidney dysfunction with eGFR < 30 ml/min/kg and/or receives dialysis
- The patient is pregnant or planning on becoming pregnant
- The patient has (chronic) iron overload
- The patient is not able to lie still in the scanner
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a single center open-label feasibility trial involving a single study visit for participants. The purpose of the study is to demonstrate the feasibility of [68Ga]Ga-DFO-B PET/CT (gallium-68-deferoxamine) for the visualization of pulmonary Aspergillus infection.
Read full original descriptionShow less
The incidence of fungal infections is on the rise and are associated with significant mortality. Diagnosis pulmonary aspergillosis can be can be challenging, often requiring invasive tests such as bronchoscopy and lung tissue biopsies. Molecular imaging, specifically using radiolabeled siderophores like [68Ga]Ga-DFO-B, offers a non-invasive and location-specific approach to visualize and evaluate infections. Siderophores, critical for pathogenic microbes like Aspergillus fumigatus, play a role in iron acquisition. Preclinical studies with radiolabeled deferoxamine (DFO-B) demonstrated distinct accumulation at infection sites. Additionally, [68Ga]Ga-DFO-B PET/CT may differentiate between Aspergillus infection and cancer, making it a promising non-invasive diagnostic tool for pulmonary aspergillosis.
The group in the trial
- InterventionTreatment being tested
Patients will undergo a PET/CT scan at t=60 min after a single intravenous injection of a fixed dose of 100 MBq +/- 10% \[68Ga\]Ga-DFO-B (gallium-68-deferoxamine) which contains 100 µg deferoxamine (DFO-B).
Treatment: Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 18 August 2026